Open-label Non-comparative Study to Evaluate the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2019
Price : $35 *
At a glance
- Drugs Netakimab (Primary) ; Ursodeoxycholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Biocad
- 09 Oct 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 02 Jul 2018 Status changed from not yet recruiting to recruiting.